Summit Packs A Punch For Merck’s Keytruda — But Not Everyone Is Sold

Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck’s blockbuster, Keytruda.

The post Summit Packs A Punch For Merck’s Keytruda — But Not Everyone Is Sold appeared first on Investor’s Business Daily.